Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa

Iannone M, Michela Iannone, Agata Janowska, Janowska A, Giulia Tonini, Tonini G, Davini G, Giulia Davini, Dini V, Valentina Dini
Clinics in dermatology · 2021 · vol. 39(4) , pp. 701–702 · doi:10.1016/j.clindermatol.2021.05.026 · PMID:34809775 · PMC8131181
Other OA: gold
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-27 ⓘ

This paper evaluates the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with hidradenitis suppurativa undergoing treatment with Ixekizumab.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

COVID-19 Hidradenitis Suppurativa Hidradenitis Suppurativa Antibodies, Monoclonal, Humanized COVID-19 Vaccines Humans RNA, Messenger SARS-CoV-2

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
pubmed
last seen: 2026-10-08T21:33:14.624860+00:00
unpaywall
last seen: 2026-10-24T06:30:43.844863+00:00